Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a Phase 0, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to assess
the changes in ERP Biomarkers in Healthy Volunteers before and after administration of a
sub-anesthetic dose of ketamine. Primary objectives are to quantify the effect size of
ketamine-induced changes on MMN from a duration-deviant auditory oddball ERP test and to
quantify the variability of ketamine-induced changes on MMN from a duration-deviant auditory
oddball ERP test.
Phase:
Early Phase 1
Details
Lead Sponsor:
ERP Biomarker Qualification Consortium
Collaborators:
Alkermes, Inc. Anavex Life Sciences Corp. Apex Innovative Sciences Astellas Pharma Inc COGNISION H. Lundbeck A/S Merck Sharp & Dohme Corp. Novartis Sage Therapeutics Takeda